The University of Texas M.D. Anderson Cancer Center is proposing a Specialized Program of Research Excellence (SPORE) in Leukemia. The primary goal of this Leukemia SPORE is to cultivate and facilitate innovative and significant translational research in the biologic, genetic and clinical aspects of leukemia to improve understanding, therapy, and prognosis. The multidisciplinary group of investigators in the Leukemia SPORE will accomplish this goal through effective integration of laboratory, epidemiologic and clinical investigations. Such activity will further our understanding of genetic susceptibility and leukemogenic molecular processes in leukemia, leading to novel, molecularly targeted strategies in leukemia. The SPORE is designed with 6 research projects and 3 core resources, as well as programs for developmental research and career development. The research projects are designed to target specific areas important in leukemia. ? Project 1 - Epigenetics of Drug Resistance in Acute Leukemia -targets methylation for therapy in leukemia ? Project 2 -Adoptive Cellular Therapy of Myeloid Leukemia - targets the use of MPO-Specific Cytotoxic T Lymphocytes (CTL) to treat leukemia ? Project 3 - Concerted Blockade of Oncoprotein Activity - targets sequential DNA, RNA and oncoprotein blockage in leukemia ? Project 4 -PPAR-gamma Nuclear Transcription Factor: A Novel Target for Leukemia Therapy - targets PPAR-gamma expression for leukemia therapy ? Project 5 - Molecular Epidemiology of AML Risk and Progression - evaluates genetic-molecular susceptibilities to development of AML through studies of relevant detoxifying and carcinogenesis-promoting pathways ? Project 6 - Response of AML Patients to FLT3 Inhibitors - targets FLT3 ligand inhibition in leukemias expressing FLT3 mutations or internal tandem duplication (ITD) ? Core and other resources are: Core A - Administration, Core B - Pathology and Tissue, Core C - Biostatistics & Data Management, Developmental Research Program, and Career Development Program. Through this leukemia SPORE, our research team will make a significant impact on leukemia prognosis. ? ? ?

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA100632-03
Application #
6937763
Study Section
Special Emphasis Panel (ZCA1-GRB-G (J1))
Program Officer
Nothwehr, Steven F
Project Start
2003-08-05
Project End
2008-04-30
Budget Start
2005-07-29
Budget End
2006-04-30
Support Year
3
Fiscal Year
2005
Total Cost
$2,492,247
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Internal Medicine/Medicine
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Sekihara, Kazumasa; Saitoh, Kaori; Han, Lina et al. (2017) Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1. Oncotarget 8:34552-34564
Johanning, Gary L; Malouf, Gabriel G; Zheng, Xiaofeng et al. (2017) Expression of human endogenous retrovirus-K is strongly associated with the basal-like breast cancer phenotype. Sci Rep 7:41960
Katerndahl, Casey D S; Heltemes-Harris, Lynn M; Willette, Mark J L et al. (2017) Antagonism of B cell enhancer networks by STAT5 drives leukemia and poor patient survival. Nat Immunol 18:694-704
Kanagal-Shamanna, Rashmi; Loghavi, Sanam; DiNardo, Courtney D et al. (2017) Bone marrow pathologic abnormalities in familial platelet disorder with propensity for myeloid malignancy and germline RUNX1 mutation. Haematologica 102:1661-1670
Mu, Yunxiang; Zelazowska, Monika A; McBride, Kevin M (2017) Phosphorylation promotes activation-induced cytidine deaminase activity at the Myc oncogene. J Exp Med 214:3543-3552
Kelly, A D; Kroeger, H; Yamazaki, J et al. (2017) A CpG island methylator phenotype in acute myeloid leukemia independent of IDH mutations and associated with a favorable outcome. Leukemia 31:2011-2019
Nieborowska-Skorska, Margaret; Sullivan, Katherine; Dasgupta, Yashodhara et al. (2017) Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cells. J Clin Invest 127:2392-2406
Pratz, Keith W; Levis, Mark (2017) How I treat FLT3-mutated AML. Blood 129:565-571
Kerros, Celine; Tripathi, Satyendra C; Zha, Dongxing et al. (2017) Neuropilin-1 mediates neutrophil elastase uptake and cross-presentation in breast cancer cells. J Biol Chem 292:10295-10305
Kayser, Sabine; Levis, Mark J (2017) Advances in targeted therapy for acute myeloid leukaemia. Br J Haematol :

Showing the most recent 10 out of 450 publications